File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia

TitlePhase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia
Authors
KeywordsPlerixafor
Children
Stem cell transplantation
Allogeneic
Issue Date2014
Citation
Biology of Blood and Marrow Transplantation, 2014, v. 20, n. 8, p. 1224-1228 How to Cite?
AbstractThe safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied. This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intravenously on day -4 (level 1); day -4 and day -3 (level 2); or day -4, day -3, and day -2 (level 3) in combination with fludarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all 3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events. The area under the concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males and increased linearly with body weight and glomerular filtration rate. The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < .001). Biologically, the proportion of CXCR4+ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor administration. © 2014 American Society for Blood and Marrow Transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/294497
ISSN
2022 Impact Factor: 4.3
2020 SCImago Journal Rankings: 2.301
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSrinivasan, Ashok-
dc.contributor.authorPanetta, John C.-
dc.contributor.authorCross, Shane J.-
dc.contributor.authorPillai, Asha-
dc.contributor.authorTriplett, Brandon M.-
dc.contributor.authorShook, David R.-
dc.contributor.authorDallas, Mari H.-
dc.contributor.authorHartford, Christine-
dc.contributor.authorSunkara, Anusha-
dc.contributor.authorKang, Guolian-
dc.contributor.authorJacobsen, Jeffrey-
dc.contributor.authorChoi, John-
dc.contributor.authorLeung, Wing-
dc.date.accessioned2020-12-03T08:22:52Z-
dc.date.available2020-12-03T08:22:52Z-
dc.date.issued2014-
dc.identifier.citationBiology of Blood and Marrow Transplantation, 2014, v. 20, n. 8, p. 1224-1228-
dc.identifier.issn1083-8791-
dc.identifier.urihttp://hdl.handle.net/10722/294497-
dc.description.abstractThe safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied. This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intravenously on day -4 (level 1); day -4 and day -3 (level 2); or day -4, day -3, and day -2 (level 3) in combination with fludarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all 3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events. The area under the concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males and increased linearly with body weight and glomerular filtration rate. The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < .001). Biologically, the proportion of CXCR4+ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor administration. © 2014 American Society for Blood and Marrow Transplantation.-
dc.languageeng-
dc.relation.ispartofBiology of Blood and Marrow Transplantation-
dc.subjectPlerixafor-
dc.subjectChildren-
dc.subjectStem cell transplantation-
dc.subjectAllogeneic-
dc.titlePhase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.bbmt.2014.04.020-
dc.identifier.pmid24769325-
dc.identifier.pmcidPMC4631218-
dc.identifier.scopuseid_2-s2.0-84904057587-
dc.identifier.volume20-
dc.identifier.issue8-
dc.identifier.spage1224-
dc.identifier.epage1228-
dc.identifier.eissn1523-6536-
dc.identifier.isiWOS:000339464100022-
dc.identifier.issnl1083-8791-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats